Skip to content

Delcath Systems

US · DCTH #3706 by market cap
15.36 +0.32 +2.13%
Live - 5344 symbols - heartbeat 95s ago · 2026-10-09 19:30

Valuation each multiple against its own 5-year range

P/B ratio 4.41 In line with history 58th percentile
5-year average -5.21 · #86 of 125 in Medical Devices
P/E ratio 1,538.00 Expensive vs history 97th percentile
5-year average 147.51 · forward -47.93 · #38 of 38 in Medical Devices
P/S ratio 5.59 Cheap vs history 19th percentile
5-year average 18.77 · forward 4.43 · #96 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Delcath Systems (DCTH) 532.97M 1,536.00 4.40 0.00%
Abbott Laboratories (ABT) 172.35B 32.23 3.37 2.45%
Medtronic (MDT) 113.18B 21.79 2.25 3.22%
Stryker Corp (SYK) 106.38B 28.74 4.43 1.25%
Boston Scientific (BSX) 61.93B 17.30 2.48 0.00%
Edwards Lifesciences (EW) 49.12B 49.54 4.63 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value15.17 Economic moatNone UncertaintyHigh

Trading 1.2% above Morningstar's fair value estimate.

Fair value

Delcath Systems Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 1% premium over our quantitative fair value estimate of $15.17 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's valuation metrics undermine our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to EBITDA ratio of 23.2 lies in the top 30% compared with global peers. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be overvalued.

The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 2.7%, for example, lies in the bottom 45% compared with global peers. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-09 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Delcath Systems discussion 0 comments

Add a comment